Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01107106 · ClinicalTrials.gov registry record
Safety, Tolerability, and Efficacy of ellaOne® (Ulipristal Acetate) for Emergency Contraception in Postmenarcheal Adolescent Girls and Women
A clinical trial of Contraception, sponsored by HRA Pharma.
- Completed
- Registry status
- 579
- Enrollment target
- 6
- Study locations
NCT01107106 is a study of Contraception that has completed, run by HRA Pharma. The registered enrollment target is 579 participants, above the 447-participant average among 72 other Contraception trials with a reported enrollment target (30% higher). The trial reports 6 study locations across 3 states.
The verdict
NCT01107106, a study of Contraception, has completed, sponsored by HRA Pharma.
- COMPLETED
- Registry status
- 579 participants
- Enrollment target
- 6
- Study locations
Study Summary
The purpose of this observational study is to assess the safety and tolerability of ellaOne® in routine conditions of use for emergency contraception in postmenarcheal adolescents and adult women who want to prevent pregnancy up to 5 days after unprotected sexual intercourse.
Conditions Studied
Interventions
- DRUG ellaOne® (ulipristal acetate)
Study Locations (6)
Colorado
- PPRM Central clinic - Denver
- PPRM Southwest clinic - Lakewood
Pennsylvania
- Elizabeth Blackwell Health Center - Philadelphia
- Locust Health Center - Philadelphia
Other
- Dept of Women & Child Health - Karolinska University Hospital - Stockholm
- Brook clinic - Belfast
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 579 participants |
| Start Date | 2010-05 |
| Est. Completion | 2013-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01107106
The ClinicalTrials.gov registry entry for NCT01107106 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 579 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 447-participant average among 72 other Contraception trials with a reported enrollment target (30% higher). The listed sponsor is HRA Pharma, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Contraception appearing as the primary indexed condition, and to 1 intervention - of which ellaOne® (ulipristal acetate) is the first listed.
NCT01107106 reports 6 study locations spanning 3 distinct geographic areas - top geographies include Colorado, Pennsylvania, Other.
Frequently Asked Questions
What is clinical trial NCT01107106 about?
NCT01107106 is a clinical study titled "Safety, Tolerability, and Efficacy of ellaOne® (Ulipristal Acetate) for Emergency Contraception in Postmenarcheal Adolescent Girls and Women". The purpose of this observational study is to assess the safety and tolerability of ellaOne® in routine conditions of use for emergency contraception in postmenarcheal adolescents and adult women who want to prevent pregnancy up to 5 days after unprotected sexual intercourse.
What is the current status of trial NCT01107106?
This trial is currently completed. The enrollment target is 579 participants. The study started on 2010-05. Estimated completion is 2013-02.
What conditions does trial NCT01107106 study?
This clinical trial studies the following conditions: Contraception.
What interventions are being tested in trial NCT01107106?
The interventions under investigation include: ellaOne® (ulipristal acetate) (DRUG).
Who is sponsoring clinical trial NCT01107106?
This trial is sponsored by HRA Pharma, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01107106 being conducted?
This trial has 6 study locations across Colorado, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Contraception
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Oral Contraceptive Pill (OCP) Pharmacogenomics
RECRUITING · Phase 4
-
Intravenous Ketorolac Administration to Attenuate Post-procedural Pain Associated With Intrauterine Device Placement
RECRUITING · Phase 4
-
Patient-clinical Linkages to Improve Trust and Engagement in Postpartum Healthcare
RECRUITING · NA
-
Empathy Through Pain Control: Lidocaine Paracervical Block for IUD Placements
RECRUITING · NA
-
Hormonal Contraception Access Through Pharmacist Prescribing Implementation
RECRUITING · NA
-
Prospective Multi-Center Trial for FemBloc Permanent Birth Control
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.